[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354448-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354448-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","antigen-spreading-via-localized-administration-enhances-adoptive-tcr-t-cell-therapy-in-pancreatic-cancer","Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer","","Cancer vaccines show early benefits, yet pancreatic cancer remains hindered by a low mutational burden that yields insufficient well-characterized tumor antigens for rejection. This study introduces the ionic liquid ILvax for localized tumor administration to drive systemic, antigen-specific anti-tumor immunity and a vaccine-like effect. Type 1 conventional dendritic cells (cDC1) govern the systemic response, initiating antigen presentation and expanding antigen-specific T cells. ILvax-induced antigen spreading boosts adoptive TCR-T expansion and shifts TCR-T metabolism toward OXPHOS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/antigen-spreading-via-localized-administration-enhances-adoptive-tcr-t-cell-therapy-in-pancreatic-cancer/354448/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/antigen-spreading-via-localized-administration-enhances-adoptive-tcr-t-cell-therapy-in-pancreatic-cancer/354448.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem limits cancer vaccination in pancreatic cancer?","Question",{"text":63,"@type":64},"A low mutational burden reduces the availability of well-characterized antigens expressed in tumors that can mediate tumor rejection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ILvax work in this study?",{"text":68,"@type":64},"ILvax is administered locally to the tumor and elicits a systemic, antigen-specific immune response with a vaccine-like effect.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is cDC1 important for the immune response?",{"text":72,"@type":64},"The study identifies type 1 conventional dendritic cells (cDC1) as the determinant for systemic immune response, driving antigen presentation and antigen-specific T cell expansion.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354448,1790137104,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Advanced Science  \n| [www.advancedscience.com](www.advancedscience.com)\u003Cbr> RESEARCH ARTICLE \u003Cbr>Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer\u003Cbr>Junming Huang1, 2  Qin Wang1, 2  Zhuo Yao1, 2   Qing Wang1, 2  Yongtao Ji1, 2  Minqi Yang1, 2  Meng Wang2, 3  Shiyi Shao1, 2  Xinyu Zhao1, 2  Fu Zhang1, 2  Tingbo Liang1, 2, 3, 4, 5, 6   Qida Hu1, 2 \u003Cbr>1 Department of Hepatobiliary and Pancreatic Surgery, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China \u003Cbr>2Zhejiang Provincial Key Laboratory of Pancreatic Disease, School of Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China \u003Cbr>3 Department of Breast Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China  4The Innovation Center For the Study of Pancreatic Diseases, Hangzhou, China  5Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China  6MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, China\u003Cbr>Correspondence: Tingbo Liang ([liangtingbo@zju.edu.cn](liangtingbo@zju.edu.cn))  Qida Hu (huqida@zju.edu.cn)\u003Cbr>Received: 15 March 2026  Revised: 4 June 2026  Accepted: 9 June 2026\u003Cbr>Keywords: antigen presentation | antigen | cancer | cancer research | cd8 | cell therapy | immune system | medicine | pancreatic cancer\u003Cbr>\u003Cbr>ABSTRACT\u003Cbr>Cancer vaccines have demonstrated initial effectiveness in the treatment of human cancers, still the low mutational burden, which leads to a deficiency of well-characterized antigens expressed within tumors capable of mediating tumor rejection, poses a significant challenge in pancreatic cancer. Here, we introduce an ionic liquid ILvax for localized tumor administration, which elicits a systemic and antigen-specific anti-tumor immune response, thereby generating a vaccine-like effect. Type 1 conventional dendritic cells (cDC1) is the determinant for systemic immune response. ILvax ablation facilitates migration of tumor antigencarrying cDC1 to peripheral lymphoid organs, thus initiating the cDC1-mediated antigen presentation cascade that results inan amplified antigen-specific T cells response. Meanwhile, cDC1-mediated antigen spreading induced by ILvax enabled the expansion of adoptive TCR-T while shifting TCR-T metabolism toward oxidative phosphorylation (OXPHOS) . Localized tumor administration with ILvax simultaneously enhances the functionality of both endogenous CD8+ T cells and adoptive TCR-T cells, offering a clinically translatable collaborative strategy against pancreatic cancer. |  |\n| --- | --- |\n| 1  Introduction\u003Cbr>Cancer immunotherapy leverages the patient’s immune system to target and combat tumors effectively. Despite significant advancements in the effective application of immunotherapy for the treatment of various solid tumors, its utilization in addressing pancreatic cancer remains challenging [1–3] . A successful cancer immunotherapy requires the activation of the cancer-immunity cycle (CIC) [4, 5] . This cycle comprises the | release of tumor antigens from cancer cells, antigen capture and processing by antigen-presenting cells (APCs), the generation of antigen-specific T cells, and finally, the lysis of tumor cell by antigen-specific T cells. In situ cancer vaccination represents a class of immunotherapeutic interventions that harness endogenous tumor-associated antigens (TAAs) localized within native tumor niches to orchestrate de novo systemic immunity while establishing immunological memory, thereby reconstituting the defective cancer-immunity cycle through sequential phase |\n| Junming Huang and Qin Wang contributed equally to this work.\u003Cbr>[Correction added on 14 July 2026, after first online publication: The section numbering was updated from 4.8 to 4.17 in this version.] |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, dist","cbCaivcXOHD7m3ju","https://ap.wps.com/l/cbCaivcXOHD7m3ju","pdf",10354867,16,"English","# Introduction\n## Cancer-immunity cycle activation\n## Antigen spreading and in situ vaccination\n## Locoregional therapy and antigen-presenting cells","[{\"question\":\"What problem limits cancer vaccination in pancreatic cancer?\",\"answer\":\"A low mutational burden reduces the availability of well-characterized antigens expressed in tumors that can mediate tumor rejection.\"},{\"question\":\"How does ILvax work in this study?\",\"answer\":\"ILvax is administered locally to the tumor and elicits a systemic, antigen-specific immune response with a vaccine-like effect.\"},{\"question\":\"Why is cDC1 important for the immune response?\",\"answer\":\"The study identifies type 1 conventional dendritic cells (cDC1) as the determinant for systemic immune response, driving antigen presentation and antigen-specific T cell expansion.\"}]","Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer | PDF",1790110688,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77c78aa12d1ac94ec933cc8c5b5acb03.webp",983,1283,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d618bd1bf0700630103f3235f9f10f3.webp",982,1281,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e4eff7306cc2fb469fc17c9c4765ec2.webp",981,1280,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/502de8405ddac33cbbf08f6370babad7.webp",980,1279]